These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 12115139)

  • 1. Structural transformation and aggregation of human alpha-synuclein in trifluoroethanol: non-amyloid component sequence is essential and beta-sheet formation is prerequisite to aggregation.
    Li HT; Du HN; Tang L; Hu J; Hu HY
    Biopolymers; 2002 Aug; 64(4):221-6. PubMed ID: 12115139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligopeptide-mediated acceleration of amyloid fibril formation of amyloid beta(Abeta) and alpha-synuclein fragment peptide (NAC).
    Kuroda Y; Maeda Y; Hanaoka H; Miyamoto K; Nakagawa T
    J Pept Sci; 2004 Jan; 10(1):8-17. PubMed ID: 14959887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.
    El-Agnaf OM; Irvine GB
    J Struct Biol; 2000 Jun; 130(2-3):300-9. PubMed ID: 10940234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. beta-sheet structure formation of proteins in solid state as revealed by circular dichroism spectroscopy.
    Hu HY; Li Q; Cheng HC; Du HN
    Biopolymers; 2001; 62(1):15-21. PubMed ID: 11135188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary structural formation of alpha-synuclein amyloids as revealed by g-factor of solid-state circular dichroism.
    Lin XJ; Zhang F; Xie YY; Bao WJ; He JH; Hu HY
    Biopolymers; 2006 Oct; 83(3):226-32. PubMed ID: 16752390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
    Park JY; Lansbury PT
    Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein.
    Du HN; Tang L; Luo XY; Li HT; Hu J; Zhou JW; Hu HY
    Biochemistry; 2003 Jul; 42(29):8870-8. PubMed ID: 12873148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid self-assembly of alpha-synuclein observed by in situ atomic force microscopy.
    Hoyer W; Cherny D; Subramaniam V; Jovin TM
    J Mol Biol; 2004 Jun; 340(1):127-39. PubMed ID: 15184027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.
    Emadi S; Liu R; Yuan B; Schulz P; McAllister C; Lyubchenko Y; Messer A; Sierks MR
    Biochemistry; 2004 Mar; 43(10):2871-8. PubMed ID: 15005622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural changes in alpha-synuclein affect its chaperone-like activity in vitro.
    Kim TD; Paik SR; Yang CH; Kim J
    Protein Sci; 2000 Dec; 9(12):2489-96. PubMed ID: 11206070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
    Volles MJ; Lansbury PT
    Biochemistry; 2003 Jul; 42(26):7871-8. PubMed ID: 12834338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synucleins and their relationship to Parkinson's disease.
    von Bohlen Und Halbach O
    Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A topological model of the interaction between alpha-synuclein and sodium dodecyl sulfate micelles.
    Bisaglia M; Tessari I; Pinato L; Bellanda M; Giraudo S; Fasano M; Bergantino E; Bubacco L; Mammi S
    Biochemistry; 2005 Jan; 44(1):329-39. PubMed ID: 15628875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation.
    Kessler JC; Rochet JC; Lansbury PT
    Biochemistry; 2003 Jan; 42(3):672-8. PubMed ID: 12534279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-synuclein exhibits chaperone activity more efficiently than alpha-synuclein.
    Lee D; Paik SR; Choi KY
    FEBS Lett; 2004 Oct; 576(1-2):256-60. PubMed ID: 15474047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of macromolecular crowding on protein aggregation and amyloid fibril formation.
    Munishkina LA; Cooper EM; Uversky VN; Fink AL
    J Mol Recognit; 2004; 17(5):456-64. PubMed ID: 15362105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity.
    Rekas A; Adda CG; Andrew Aquilina J; Barnham KJ; Sunde M; Galatis D; Williamson NA; Masters CL; Anders RF; Robinson CV; Cappai R; Carver JA
    J Mol Biol; 2004 Jul; 340(5):1167-83. PubMed ID: 15236975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forcing nonamyloidogenic beta-synuclein to fibrillate.
    Yamin G; Munishkina LA; Karymov MA; Lyubchenko YL; Uversky VN; Fink AL
    Biochemistry; 2005 Jun; 44(25):9096-107. PubMed ID: 15966733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The aggregation and membrane-binding properties of an alpha-synuclein peptide fragment.
    Madine J; Doig AJ; Middleton DA
    Biochem Soc Trans; 2004 Dec; 32(Pt 6):1127-9. PubMed ID: 15506987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PA700, the regulatory complex of the 26S proteasome, interferes with alpha-synuclein assembly.
    Ghee M; Melki R; Michot N; Mallet J
    FEBS J; 2005 Aug; 272(16):4023-33. PubMed ID: 16098186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.